Clinical Trials
4 trialsNCT03732820 2026-06-02
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT05171816 2026-03-11
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
AstraZeneca
Phase 3 Active not recruiting
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02987543 2023-10-06
Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
AstraZeneca
Phase 3 Completed